The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which ...

The study was designed to evaluate Zepbound compared with Novo Nordisk's Wegovy in adults with obesity with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep ...

Eli Lilly's obesity drug Zepbound showed 47% more weight loss than Novo Nordisk's Wegovy in a major comparative trial. The ...

Kara Kennedy's husband was a yo-yo dieter for decades, until he discovered Zepbound – an Ozempic-like drug – and lost 3.5 ...

Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's ...

The outgoing Biden administration is proposing to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid, and the director of WVU Medicine’s medical weight ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...